Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
111In-XYIMSR-01 SPECT/CT in Metastatic Clear Cell Renal Cell Carcinoma
NCT07062549Phase 1Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2022
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 111In-XYIMSR-01 in renal cell carcinoma (RCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Number of adverse events at 1 week. Started Jan 2022; status: recruiting.
02
Drugs
111In-XYIMSR-01
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07062549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07062549.